Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval ...

AUSTIN, TX - March 19, 2026 - Published research in Molecular Psychiatry evaluating folinic acid supplementation in ...

Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 /Actuate Therapeutics, ...

A valved holding chamber with high drug delivery performance may reduce wheezing severity and hospitalizations more ...

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Melatonin is now widely used to help children sleep, but scientists say the enthusiasm may be getting ahead of the evidence.

OXOS Medical® today announced that its MC2 portable X-ray system is now cleared for pediatric imaging, enabling providers to deliver quality, low-dose X-ray imaging to young patients. This press ...

Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to ...

Off-label adjunctive use requires careful dosing, dose adjustments of insulin and other medications, and close monitoring.

Comprehensive analyses identified children aged 3 to 12 years and fast progressors with mild to moderate myopia as the populations with greatest treatment benefit Data demonstrated consistent ...

Get unlimited access to breaking news, ancestry archives, our daily E-newspaper, games and more. Subscribe Today » ...